This document provides information about the 10th Advanced International Breast Cancer Course (AIBCC) taking place from November 6-8, 2014 in Padua, Italy. The conference will include lectures from internationally recognized speakers on topics related to breast cancer diagnosis, treatment, and management. It will also include clinical case discussions where difficult cases are presented and attendees vote and discuss treatment options. The goal of the conference is to provide an updated and personalized approach to breast cancer care through an exchange of expertise between speakers and attendees. The conference is directed at oncologists, surgeons, pathologists, and other medical professionals involved in breast cancer treatment.

1. Section of Oncology
1 di 6
[ Meet the Professor ]
10th Meet The Professor
Advanced International Breast Cancer Course
(AIBCC)
Padua, November 6-8, 2014
The Conference will include:
1) Lectures:
Internationally recognized speakers provide a balanced overview of selected topics
2) Clinical Case Discussions:
Difficult or controversial cases related to the diagnostic or therapeutic management of early and advanced
breast cancer will be presented. All participants will be requested to express their vote among a predefined
list of options.
Expert panelists will then provide their opinion and discuss the audience choices.
3) Highlights:
Internationally recognized speakers give an update of significant advances presented at major meetings
(ASCO, ESMO, SABCS) on preselected topics

2. Section of Oncology
2 di 6
[ Preliminary Program]
Thursday, November 6th
8.00 Registration
8.45 Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi
SESSION I
PATHOLOGY
9.00 Standardization of breast cancer diagnosis: pathology
Giuseppe Viale
9.30 Standardization of breast cancer diagnosis: genomics
Giampaolo Bianchini
SESSION II
LOCO-REGIONAL THERAPIES
10.00 Evolving loco-regional management
 Do margins still matter - Alberto Costa
 Sentinel node biopsy and axillary node dissection: does radiotherapy matter? – TBD
 Hypofractionated breast irradiation- Philip Poortmans
11.00 Coffee break
SESSION III
IMAGING
11.30 MRI in breast cancer diagnosis
3 clinical cases will be presented by a young doctor (local faculty). The following items will be
discussed:
- Is MRI the standard screening procedure in young women?
- Is MRI the gold standard to assess the response to neoadjuvant therapy?
- Is MRI appropriate to plan type of surgery?
The audience will be asked to vote. After the vote, two senior speakers (TBD) will discuss items in
favor or contra. The audience will be asked to vote again after the discussion.
13.00 Lunch
SESSION IV
STAGING AND ADJUVANT
14.00 Appropriate work out staging in early breast cancer
TBD

3. Section of Oncology
3 di 6
14.30 Is there a role for adjuvant bisphosphonates?
Robert Coleman
SESSION V
GUIDELINES
15.00 Role of guidelines in the era of personalized cancer medicine
- do guidelines impact on patients outcome? TBD
- how to reconcile the increasing complexity of breast tumors in simple guidelines TBD
16.30 Adjourn
17.30 Ceremony for the presentation of the University of Padua Award for Advances Breast Cancer
2014 and the Monica Boscolo Research Grant
18.00 Lecture of the Awardee
18.30 Adjourn
Friday, November 7th
SESSION VI
EARLY BREAST CANCER
9.00 Adjuvant – Clinical Case Discussion I
1 presenter and 1 discussant each (with tele voting)
- Fertility preservation. Presenter: local faculty. Discussant: TBD
- Adjuvant therapy for low risk HER2+ patients. Presenter: local faculty. Discussant: TBD
- Adjuvant chemotherapy for HR? Presenter: local faculty. Discussant: TBD
11.00 Coffee break
11.30 Neoadjuvant – Clinical Case Discussion II
1 presenter and 1 discussant each (with tele voting)
- HR+/HER2 negative. Presenter: local faculty. Discussant: TBD
- Adjuvant therapy in suboptimal responders after neoadjuvant therapy. Presenter: local faculty.
Discussant: TBD
- Triple negative breast cancer (platinum salts, BRCA testing). Presenter: local faculty. Discussant:
TBD
13.30 Lunch
SESSION VII
ADVANCED BREAST CANCER
14.30 Clinical case discussion III
1 presenter and 1 discussant each (with tele voting)
- Sequence and duration of anti-HER2 therapy. Presenter: local faculty. Discussant: TBD
- New landscape of treatment for HR+ disease. Presenter: local faculty. Discussant: TBD
- Triple negative advanced breast cancer. Presenter: local faculty. Discussant: TBD

4. Section of Oncology
4 di 6
16.00 Coffee break
16.30 Clinical case discussion IV
1 presenter and 1 discussant each (with tele voting)
- Loco-regional treatments for CNS metastases. Presenter: local faculty. Discussant: TBD
- Surgery of the primary in de novo stage IV disease. Presenter: local faculty. Discussant: TBD
18.00 Adjourn
Saturday, November 8th
SESSION VIII
HIGHLIGHTS OF THE YEAR
9.00 Advances in biology
TBD
9.30 HER2+ early and advanced disease
TBD
10.00 HR+/HER2- early and advanced disease
TBD
10.30 Triple negative early and advanced disease
TBD
11.00 Coffee break
SESSION IX
COMING SOON
11.30 New promising drugs
TBD
12.00 Trials likely to impact on clinical practice in the near future: EBC
TBD
12.30 Trials likely to impact on clinical practice in the near future: ABC
TBD
13.00 Adjourn and final evaluation questionnaire
[ Aims]
Breast cancer mortality is declining in most countries as a result of advances in the knowledge of the
mechanisms of cancer progression, phenotypic and genotypic characterization of the disease, screening
programs, advanced imaging, local therapies and molecularly targeted drugs. Nowadays, breast cancer
represents the front runner in the path to comparative effectiveness where new therapeutic interventions
are implemented on the basis of “average” benefit to personalized cancer medicine where the right
treatment is provided to the right patient at the right moment. An updated, multifaceted approach to our
patients is now becoming more and more demanding and with these goals in mind, the Programme of this
international Conference includes lectures on the molecular characterization, updated management of early

5. Section of Oncology
5 di 6
and advanced disease, strategies to overcome resistance to available therapies, innovative therapies, and
multimodal treatments for advanced disease. Clinical case discussions and debates are planned to allow a
continuous and fruitful exchange of experiences and opinions between speakers and participants.
This 10th
Breast Cancer Conference includes a highly qualified international faculty, but will maintain its
characteristics of a friendly forum where international opinion leaders and attendees will exchange
experiences and share the most exiting advances.
In order to reward scientific excellence and to foster international cooperation, the International Scientific
Committee of the 10th
AIBCC will award the 4th
International Prize for Breast Cancer Research to a scientist
who has published a breakthrough paper in the previous year and the Monica Boscolo Research Grant to an
Italian scientist for a research project to be conducted in cooperation with a foreign institution.
We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to
listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.
[ Addressed to]
Oncologists, biologists, pathologists, radiologists, radiation oncologists, surgeons, gynaecologists, biologists
and nurses.
[ Directors ]
Pier Franco Conte
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Gabriel N. Hortobagyi
Department of Breast Medical Oncology
University of Texas - MD Anderson Cancer Center
Houston (USA)
[ Scientific Committee]
Jonas Bergh
Department of Oncology-Pathology
Karolinska Institute and University Hospital
Stockholm (SW)
Valentina Guarneri
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)
Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

6. Section of Oncology
6 di 6
Sibylle Loibl
German Breast Group
Department of Medicine and Reasearch
University of Frankfurt (D)
Miguel Martin
Medical Oncology Service
Hospital Universitario Gregorio Maranon
Madrid (S)
Donato Nitti
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Philip Poortmans
President-elect of ESTRO
Department of Radiation Oncology
Dr. Verbeeten Instituut
Tilburg (NL)
[ Meeting Venue]
Centro Congressi Padova “A. Luciani”
Via Forcellini, 170/A
Padova
tel. 049/8033711